DBD
NEUTRAL
$85.64
Live
Diebold Nixdorf, Incorporated · NYSE
Target $96.67
(+12.9%)
$43.0
52W Range
$89.05
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 26, 2026
Market cap
$2.98B
P/E
33.72
ROE
9.5%
Profit margin
2.5%
Debt/Equity
0.99
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
DBD presents a stark dichotomy between explosive earnings growth and concerning sentiment indicators. With a Piotroski F-Score of 4/9, the company's financial health is categorized as stable but lacks strong momentum. While the stock currently trades at a premium to its Graham Number ($42.15) and Intrinsic Value ($74.93), the low forward P/E of 12.75 suggests the market is pricing in continued earnings acceleration. However, heavy insider liquidation and a bearish technical trend significantly offset the strong analyst 'strong_buy' consensus.
Key Strengths
Explosive YoY earnings growth of 815.40%
Strong earnings track record with 3/4 recent beats and high average surprise (39.13%)
Attractive Price/Sales ratio of 0.78, suggesting undervaluation relative to top-line revenue
Significant compression in Forward P/E (12.75) compared to Trailing P/E (33.72)
Consistent double-digit revenue growth (11.70% YoY)
Key Risks
Heavy insider selling totaling $92.42M by major beneficial owners
Current price ($85.64) exceeds both Graham and Intrinsic value estimates
Weak technical trend score (10/100) indicating bearish price action
Mediocre Piotroski F-Score (4/9) suggesting stagnant financial health improvements
Low Quick Ratio (0.73) indicating potential short-term liquidity pressure
AI Fair Value Estimate
Based on comprehensive analysis
$78.5
-8.3% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
55
Moderate
45
88
92
50
0
AI Verdict
Speculative Growth
Key drivers: Earnings acceleration, Insider divestment, Valuation premium
Confidence
90%
Value
45/100
Trades at a premium to defensive fair value ($42.15) but looks cheap on a forward earnings basis.
Positives
- Low Price/Sales
- Low Forward P/E
Watchpoints
- Price > Graham Number
- Price > Intrinsic Value
Future
88/100
Growth metrics are the primary bullish driver for the stock.
Positives
- Massive EPS growth
- Strong revenue trajectory
- Consistent earnings beats
Watchpoints
- Sustainability of 800%+ growth is questionable
Past
92/100
Exceptional historical price appreciation over the last year.
Positives
- 1Y return of +97.7%
- Strong 3Y/5Y performance
Watchpoints
- Recent 1W dip
Health
50/100
Piotroski F-Score of 4/9 indicates a stable but non-improving financial condition.
Positives
- Current ratio > 1.0
- Stable Piotroski score
Watchpoints
- Debt/Equity near 1.0
- Quick ratio below 1.0
Dividend
0/100
Company is not returning capital to shareholders via dividends.
Positives
No standout positives identified.
Watchpoints
- No dividend payments
- 0% payout ratio
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$85.64
Analyst Target
$96.67
Upside/Downside
+12.9%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for DBD and closest competitors.
Updated 2026-04-24
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
DBD
Diebold Nixdorf, Incorporated
Primary
|
+316.3% | +316.3% | +97.7% | +45.8% | +7.9% | -3.5% |
|
QLYS
Qualys, Inc.
Peer
|
-21.9% | -34.5% | -31.1% | -34.3% | -13.9% | +9.2% |
|
RUN
Sunrun Inc.
Peer
|
-74.5% | -38.9% | +81.0% | -36.4% | -3.0% | -6.6% |
|
ACMR
ACM Research, Inc.
Peer
|
+47.7% | +266.9% | +69.0% | +55.3% | -34.4% | +3.2% |
|
LIF
Life360, Inc.
Peer
|
+41.1% | +41.1% | +12.2% | -63.5% | -15.5% | -5.8% |
DBD
Diebold Nixdorf, Incorporated
Primary
5Y
+316.3%
3Y
+316.3%
1Y
+97.7%
6M
+45.8%
1M
+7.9%
1W
-3.5%
QLY
Qualys, Inc.
Peer
5Y
-21.9%
3Y
-34.5%
1Y
-31.1%
6M
-34.3%
1M
-13.9%
1W
+9.2%
RUN
Sunrun Inc.
Peer
5Y
-74.5%
3Y
-38.9%
1Y
+81.0%
6M
-36.4%
1M
-3.0%
1W
-6.6%
ACM
ACM Research, Inc.
Peer
5Y
+47.7%
3Y
+266.9%
1Y
+69.0%
6M
+55.3%
1M
-34.4%
1W
+3.2%
LIF
Life360, Inc.
Peer
5Y
+41.1%
3Y
+41.1%
1Y
+12.2%
6M
-63.5%
1M
-15.5%
1W
-5.8%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
33.72
Forward P/E
12.75
PEG Ratio
N/A
P/B Ratio
2.76
P/S Ratio
0.78
EV/Revenue
0.97
EV/EBITDA
8.19
Market Cap
$2.98B
Profitability
Profit margins and return metrics
Profit Margin
2.49%
Operating Margin
11.57%
Gross Margin
26.37%
ROE
9.54%
ROA
5.68%
Growth
Revenue and earnings growth rates
Revenue Growth
+11.7%
Earnings Growth
+815.4%
Q/Q Revenue Growth
+11.66%
Q/Q Earnings Growth
+785.7%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.99
Moderate
Current Ratio
1.3
Good
Quick Ratio
0.73
Poor
Cash/Share
$11.31
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$1.1B
Gross Margin
25.3%
Op. Margin
7.5%
Net Margin
4.5%
Total Assets
$3.9B
Liabilities
$2.7B
Equity
$1.1B
Debt/Equity
2.50x
Operating CF
$0.2B
CapEx
$-0.0B
Free Cash Flow
$0.2B
FCF Yield
90%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-04-30
$N/A
2026-02-12
$2.75
+66.7% surprise
2025-11-05
$1.38
+47.9% surprise
2025-08-06
$0.6
+2.9% surprise
Technology Sector Comparison
Comparing DBD against 542 companies in the Technology sector
(46 bullish, 183 neutral, 313 bearish)
P/E Ratio
33.72
This Stock
vs
83.93
Sector Avg
-59.8%
(Discount)
Return on Equity (ROE)
9.54%
This Stock
vs
-35.44%
Sector Avg
-126.9%
(Below Avg)
Profit Margin
2.49%
This Stock
vs
-12.42%
Sector Avg
-120.0%
(Weaker)
Debt to Equity
0.99
This Stock
vs
0.7
Sector Avg
+40.9%
(Higher)
Revenue Growth
11.7%
This Stock
vs
4573.41%
Sector Avg
-99.7%
(Slower)
Current Ratio
1.3
This Stock
vs
3.64
Sector Avg
-64.2%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
DBD
Diebold Nixdorf, Incorporated
|
NEUTRAL | $2.98B | 33.72 | 9.5% | 2.5% | $85.64 | |
|
QLYS
Qualys, Inc.
|
NEUTRAL | $2.98B | 15.46 | 38.2% | 29.6% | $83.17 | Compare |
|
RUN
Sunrun Inc.
|
BEARISH | $2.92B | 7.25 | -22.1% | 15.2% | $12.4 | Compare |
|
ACMR
ACM Research, Inc.
|
BEARISH | $3.05B | 33.85 | 8.1% | 10.4% | $46.38 | Compare |
|
LIF
Life360, Inc.
|
NEUTRAL | $3.06B | 21.53 | 33.3% | 30.8% | $38.1 | Compare |
DBD
Diebold Nixdorf,...
NEUTRAL
Mkt Cap
$3.0B
P/E
33.7
ROE
9.5%
Price
$85.64
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-16 | MILLSTREET CAPITAL MANAGEMENT LLC | Beneficial Owner of more than 10% of a Class of Security | Sale | 112,305 | $9,554,388 |
| 2026-04-08 | MILLSTREET CAPITAL MANAGEMENT LLC | Beneficial Owner of more than 10% of a Class of Security | Sale | 399,929 | $32,960,468 |
| 2026-02-27 | TIMKO THOMAS S. | Chief Financial Officer | Stock Award | 15,308 | - |
| 2026-02-27 | SESPLANKIS JEFFREY M | Officer | Stock Award | 2,215 | - |
| 2026-02-27 | MARQUEZ OCTAVIO | Chief Executive Officer | Stock Award | 44,286 | - |
| 2026-02-27 | MYERS JONATHAN | Officer | Stock Award | 9,448 | - |
| 2026-02-27 | BAUR FRANK TOBIAS | Chief Operating Officer | Stock Award | 7,589 | - |
| 2026-02-27 | RADIGAN ELIZABETH CHRISTINE | Officer | Stock Award | 6,607 | - |
| 2026-02-27 | ZOSEL ANDREW JOSEPH | Chief Technology Officer | Stock Award | 6,561 | - |
| 2026-01-15 | MILLSTREET CAPITAL MANAGEMENT LLC | Beneficial Owner of more than 10% of a Class of Security | Sale | 500,000 | $34,000,000 |
| 2025-11-06 | MILLSTREET CAPITAL MANAGEMENT LLC | Beneficial Owner of more than 10% of a Class of Security | Sale | 251,726 | $15,906,630 |
MILLSTREET CAPITAL MANAGEMENT LLC
Beneficial Owner of more than 10% of a Class of Security
2026-04-16
112,305 shares
·
$9,554,388
MILLSTREET CAPITAL MANAGEMENT LLC
Beneficial Owner of more than 10% of a Class of Security
2026-04-08
399,929 shares
·
$32,960,468
TIMKO THOMAS S.
Chief Financial Officer
2026-02-27
15,308 shares
SESPLANKIS JEFFREY M
Officer
2026-02-27
2,215 shares
MARQUEZ OCTAVIO
Chief Executive Officer
2026-02-27
44,286 shares
MYERS JONATHAN
Officer
2026-02-27
9,448 shares
BAUR FRANK TOBIAS
Chief Operating Officer
2026-02-27
7,589 shares
RADIGAN ELIZABETH CHRISTINE
Officer
2026-02-27
6,607 shares
ZOSEL ANDREW JOSEPH
Chief Technology Officer
2026-02-27
6,561 shares
MILLSTREET CAPITAL MANAGEMENT LLC
Beneficial Owner of more than 10% of a Class of Security
2026-01-15
500,000 shares
·
$34,000,000
MILLSTREET CAPITAL MANAGEMENT LLC
Beneficial Owner of more than 10% of a Class of Security
2025-11-06
251,726 shares
·
$15,906,630
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
3 analysts
DA Davidson
2026-04-21
Buy
Buy
DA Davidson
2026-02-13
Buy
Buy
Wedbush
2026-02-13
Outperform
Outperform
Wedbush
2026-02-09
Outperform
Outperform
Wedbush
2025-11-18
Outperform
Outperform
Wedbush
2025-11-06
Outperform
Outperform
Wedbush
2025-10-28
Outperform
Outperform
Past News Coverage
Recent headlines mentioning DBD from our newsroom.
Newest → oldest
No matching news yet.